Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 5/20 | 0.52 |
| ▸ | F10 | P00742 | 9/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3290063 | 0.89 | LMNA (0.50) | TP53LMNAENPP2 | |
| SCHEMBL2766277 | 0.87 | LMNA (0.43) | TP53LMNAF10 | |
| SCHEMBL2767374 | 0.84 | LMNA (0.59) | TP53LMNAMAPT | |
| SCHEMBL3286666 | 0.82 | TP53 (0.48) | TP53LMNAF10MAPTENPP2 | |
| SCHEMBL13376561 | 0.81 | LMNA (0.52) | TP53LMNAMAPT | |
| SCHEMBL2766128 | 0.81 | LMNA (0.51) | TP53LMNAMAPT | |
| SCHEMBL3290069 | 0.79 | LMNA (0.58) | TP53LMNAMAPTENPP2 | |
| SCHEMBL2767413 | 0.78 | TP53 (0.41) | TP53LMNAMAPT | |
| SCHEMBL4515461 | 0.74 | F10 (0.64) | TP53LMNAF10F2 | |
| SCHEMBL3285450 | 0.74 | F10 (0.55) | TP53LMNAF10F2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-7714000-B2 | Substituted pyrrolidinones and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217435-A1 | New Substituted Pyrrolidinones and Their Use as Medicaments | PYCR1, S100A9, REV1 | TP53 3318/4885LMNA 1767/4885F10 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.